ClinicalTrials.Veeva

Find clinical trials for Multiple Myeloma in Paris, Île-de-France

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Plasma Cell Cancer
Lymphoma
Hematologic Cancer
Leukemia
Cancer
Smoldering Multiple Myeloma
Non-Hodgkin Lymphoma

Multiple Myeloma trials near Paris, Île-de-France, FRA:

A Study to Evaluate 3 Dose Schedules of Daratumumab in Participants With Smoldering Multiple Myeloma

The purpose of this study is to evaluate three daratumumab dose schedules in participants with Smoldering Multiple Myeloma....

Active, not recruiting
Multiple Myeloma
Drug: daratumumab

Phase 2

Janssen
Janssen

Paris, France and 56 other locations

(DRd) to that of lenalidomide and dexamethasone (Rd), in terms of progression-free survival in participants with relapsed or refractory multiple...

Active, not recruiting
Multiple Myeloma
Drug: Lenalidomide
Drug: Daratumumab

Phase 3

Janssen
Janssen

Paris, France and 145 other locations

Patients with relapsed/refractory multiple myeloma will be enrolled in a dose-escalation phase receiving monotherapy CID-103. Once ...

Active, not recruiting
Multiple Myeloma
Drug: CID-103

Phase 1

CASI Pharmaceuticals

Villejuif Cedex, France and 3 other locations

Status recently updated

CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple...

Enrolling
Active, not recruiting
Multiple Myeloma
Biological: PHE885

Phase 2

Novartis
Novartis

Paris 10, France and 37 other locations

of these combinations in participants with relapsed or refractory multiple myeloma. The study will consist of 3 distinct parts: Par ...

Active, not recruiting
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 2

AbbVie
AbbVie

Paris, France and 39 other locations

versus standard regimens in subjects with relapsed and refractory multiple myeloma (RRMM).The study is anticipated to randomize app...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Carfilzomib

Phase 3

Celgene
Celgene

Paris, France and 59 other locations

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical ben...

Enrolling
Multiple Myeloma
Drug: Elranatamab

Phase 4

Pfizer
Pfizer

Paris, France and 12 other locations

versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) followed by Autologous Stem Cell Transplant (ASCT) in newly diagnosed multiple...

Enrolling
Multiple Myeloma
Drug: Bortezomib
Drug: Daratumumab

Phase 3

Stichting European Myeloma Network

Paris, France and 119 other locations

progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not ...

Active, not recruiting
Multiple Myeloma
Drug: Daratumumab SC
Drug: Daratumumab IV

Phase 3

Janssen
Janssen

Paris, France and 211 other locations

New

This is a Phase 2 study, open-label, 2-cohort, multicenter, national, interventional in patients with newly diagnosed multiple myeloma...

Begins enrollment this month
Multiple Myeloma
Drug: Daratumumab
Drug: Dexamethasone

Phase 2

Nantes University Hospital (NUH)

Paris, France and 19 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems